Novavax’s COVID-19 vaccine could be added to the UK’s growing arsenal of shots against the disease after it showed 89.3% efficacy in a late-stage trial.
In medical research, trust has traditionally been hard-fought for. Terms like “lab rats” and “guinea pigs” are often used in conversations about clinical trials.
The ABPI’s chief executive Dr Richard Torbett shares his views on how the industry has adapted to COVID-19 and explains why the post-pandemic future is looking bright for the UK industry.
In the hours after Pfizer’s momentous vaccine news emerged on Monday #pfizerproud popped up on my social media feeds again and again from the firm’s employees, both past and present.
Professor Jean-Pierre Boissel outlines the urgent need for disruptive R&D approaches that can tackle the search for COVID-19 treatments more effectively.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.